Hypertrichosis Of Eyelid — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hypertrichosis of eyelid. 9 active patents protecting 1 drugs from 0+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
9
Active US patents
52/100
Avg vulnerability
—
Annual revenue covered

Originators in Hypertrichosis Of Eyelid

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hypertrichosis of eyelid. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
26
2
27
1
29
1
31
2
34
1
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lumigan
BIMATOPROST
 — 9 52 — 2026-12-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8206737 Lumigan method of use 80 2027-04-07
10314780 Lumigan method of use 75 2036-06-08
9980974 Lumigan method of use 62 2034-10-31
9149428 Lumigan formulation 60 2026-12-19
10441543 Lumigan formulation 60 2026-12-19
7799336 Lumigan formulation 55 2029-04-24
9492316 Lumigan formulation 42 2034-10-31
7851504 Lumigan composition of matter 22 2027-06-13
8629185 Lumigan composition of matter 10 2031-07-15

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8629185 Lumigan composition of matter 10 2031-07-15
7851504 Lumigan composition of matter 22 2027-06-13
9492316 Lumigan formulation 42 2034-10-31
7799336 Lumigan formulation 55 2029-04-24
9149428 Lumigan formulation 60 2026-12-19
10441543 Lumigan formulation 60 2026-12-19
9980974 Lumigan method of use 62 2034-10-31
10314780 Lumigan method of use 75 2036-06-08
8206737 Lumigan method of use 80 2027-04-07

Related